Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies

References

• American Diabetes Association and others (2014), “Standards of Medical Care in Diabetes 2014,” Diabetes Care, 37, S14–S80.
   PubMed Web of Science ®Google Scholar
• Belle, D. J., and Singh, H. (2008), “Genetic Factors in Drug Metabolism,” American Family Physician, 77, 1553–1560.
   PubMed Web of Science ®Google Scholar
• Buse, J. B., Wolffenbuttel, B. H., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., and Martin, S. A. (2009), “DURAbility of Basal Versus Lispro mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and Efficacy of Insulin Lispro mix 75/25 Versus Insulin Glargine Added to Oral Antihyperglycemic Drugs in Patients With Type 2 Diabetes,” Diabetes Care, 32, 1007–1013.
   PubMed Web of Science ®Google Scholar
• Cai, T., Tian, L., Wong, P. H., and Wei, L. (2011), “Analysis of Randomized Comparative Clinical Trial Data for Personalized Treatment Selections,” Biostatistics, 12, 270–282.
   PubMed Web of Science ®Google Scholar
• Cryer, P. E. (2002), “Hypoglycaemia: The Limiting Factor in the Glycaemic Management of Type I and Type II Diabetes,” Diabetologia, 45, 937–948.
   PubMed Web of Science ®Google Scholar
• Cryer, P. E., Davis, S. N., and Shamoon, H. (2003), “Hypoglycemia in Diabetes,” Diabetes Care, 26, 1902–1912.
   PubMed Web of Science ®Google Scholar
• Fahrbach, J., Jacober, S., Jiang, H., and Martin, S. (2008), “The DURABLE Trial Study Design: Comparing the Safety, Efficacy, and Durability of Insulin Glargine to Insulin Lispro mix 75/25 Added to Oral Antihyperglycemic Agents in Patients With Type 2 Diabetes,” Journal of Diabetes Science and Technology, 2, 831–838.
   PubMedGoogle Scholar
• Fidler, C., Elmelund Christensen, T., and Gillard, S. (2011), “Hypoglycemia: An Overview of Fear of Hypoglycemia, Quality-of-Life, and Impact on Costs,” Journal of Medical Economics, 14, 646–655.
   PubMedGoogle Scholar
• Foster, J. C., Taylor, J. M., and Ruberg, S. J. (2011), “Subgroup Identification From Randomized Clinical Trial Data,” Statistics in Medicine, 30, 2867–2880.
   PubMed Web of Science ®Google Scholar
• Guo, J. J., Pandey, S., Doyle, J., Bian, B., Lis, Y., and Raisch, D. W. (2010), “A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy Report of the ISPOR Risk–Benefit Management Working Group,” Value in Health, 13, 657–666.
   PubMed Web of Science ®Google Scholar
• Houede, N., Thall, P. F., Nguyen, H., Paoletti, X., and Kramar, A. (2010), “Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials,” Biometrics, 66, 532–540.
   PubMed Web of Science ®Google Scholar
• Huang, X., Shi, L., and Suykens, J. A. (2014), “Ramp Loss Linear Programming Support Vector Machine,” The Journal of Machine Learning Research, 15, 2185–2211.
   Web of Science ®Google Scholar
• Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., and Matthews, D. R. (2012), “Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, 35, 1364–1379.
   PubMed Web of Science ®Google Scholar
• Jaakkola, T., Diekhans, M., and Haussler, D. (1999), “Using the Fisher Kernel Method to Detect Remote Protein Homologies,” in ISMB (Vol. 99), pp. 149–158.
   Google Scholar
• Kosorok, M. R., and Moodie, E. E. (2015), Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine (Vol. 21), Philadelphia, PA: SIAM.
   Google Scholar
• Laber, E. B., Lizotte, D. J., and Ferguson, B. (2014), “Set-Valued Dynamic Treatment Regimes for Competing Outcomes,” Biometrics, 70, 53–61.
   PubMed Web of Science ®Google Scholar
• Lee, J., Thall, P. F., Ji, Y., and Müller, P. (2015), “Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity,” Journal of the American Statistical Association, 110, 711–722.
   PubMed Web of Science ®Google Scholar
• Lee, Y., Lin, Y., and Wahba, G. (2004), “Multicategory Support Vector Machines: Theory and Application to the Classification of Microarray Data and Satellite Radiance Data,” Journal of the American Statistical Association, 99, 67–81.
   Web of Science ®Google Scholar
• Lipkovich, I., Dmitrienko, A., Denne, J., and Enas, G. (2011), “Subgroup Identification Based on Differential Effect Search a Recursive Partitioning Method for Establishing Response to Treatment in Patient Subpopulations,” Statistics in Medicine, 30, 2601–2621.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Wang, Y., Kosorok, M., Zhao, Y., and Zeng, D. (2014), “Robust Hybrid Learning for Estimating Personalized Dynamic Treatment Regimens,” arXiv preprint arXiv:1611.02314.
   Google Scholar
• Liu, Y., and Yuan, M. (2011), “Reinforced Multicategory Support Vector Machines,” Journal of Computational and Graphical Statistics, 20, 901–919.
   Web of Science ®Google Scholar
• Lizotte, D. J., Bowling, M., and Murphy, S. A. (2012), “Linear Fitted-q Iteration With Multiple Reward Functions,” Journal of Machine Learning Research, 13, 3253–3295.
   PubMed Web of Science ®Google Scholar
• Luedtke, A. R., and Van Der Laan, M. J. (2016), “Statistical Inference for the Mean Outcome Under a Possibly Non-Unique Optimal Treatment Strategy,” The Annals of Statistics, 44, 713–742.
   PubMed Web of Science ®Google Scholar
• Lynd, L. (2006), “Quantitative Methods for Therapeutic Risk-Benefit Analysis,” in 11th International Meetings of the International Society for Pharmacoeconomics and Outcomes Research, Issues Panel: Health Outcomes Approaches to Risk-Benefit Analysis: How Ready are They.
   Google Scholar
• Moore, R. A., Derry, S., McQuay, H. J., and Paling, J. (2008), “What Do We Know About Communicating Risk? A Brief Review and Suggestion for Contextualising Serious, But Rare, Risk, and the Example of Cox-2 Selective and Nonselective NSAIDs,” Arthritis Research and Therapy, 10, R20.
   PubMed Web of Science ®Google Scholar
• Natarajan, B. K. (1995), “Sparse Approximate Solutions to Linear Systems,” SIAM Journal on Computing, 24, 227–234.
   Web of Science ®Google Scholar
• Qian, M., and Murphy, S. A. (2011), “Performance Guarantees for Individualized Treatment Rules,” Annals of Statistics, 39, 1180–1210.
   PubMed Web of Science ®Google Scholar
• Quilliam, B. J., Simeone, J. C., Ozbay, A. B., and Kogut, S. J. (2011), “The Incidence and Costs of Hypoglycemia in Type 2 Diabetes,” The American Journal of Managed Care, 17, 673–680.
   PubMed Web of Science ®Google Scholar
• Sinclair, A., Dunning, T., and Rodriguez-Mañas, L. (2015), “Diabetes in Older People: New Insights and Remaining Challenges,” The Lancet Diabetes & Endocrinology, 3, 275–285.
   PubMed Web of Science ®Google Scholar
• Su, X., Tsai, C.-L., Wang, H., Nickerson, D. M., and Li, B. (2009), “Subgroup Analysis via Recursive Partitioning,” The Journal of Machine Learning Research, 10, 141–158.
   Web of Science ®Google Scholar
• Sutton, A. J., Cooper, N. J., Abrams, K. R., Lambert, P. C., and Jones, D. R. (2005), “A Bayesian Approach to Evaluating Net Clinical Benefit Allowed for Parameter Uncertainty,” Journal of Clinical Epidemiology, 58, 26–40.
   PubMed Web of Science ®Google Scholar
• Tao, P. D., and An, L. T. H. (1998), “A DC Optimization Algorithm for Solving the Trust-Region Subproblem,” SIAM Journal on Optimization, 8, 476–505.
   Web of Science ®Google Scholar
• Thall, P. F. (2012), “Bayesian Adaptive Dose-Finding Based on Efficacy and Toxicity,” Journal of Statistical Research, 14, 187–202.
   Google Scholar
• Thall, P. F., Nguyen, H. Q., and Estey, E. H. (2008), “Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates,” Biometrics, 64, 1126–1136.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group (1998), “Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33),” The Lancet, 352, 837–853.
   Google Scholar
• Wu, Y., Zhang, H. H., and Liu, Y. (2010), “Robust Model-Free Multiclass Probability Estimation,” Journal of the American Statistical Association, 105, 424–436.
   PubMed Web of Science ®Google Scholar
• Zhang, B., Tsiatis, A. A., Laber, E. B., and Davidian, M. (2012), “A Robust Method for Estimating Optimal Treatment Regimes,” Biometrics, 68, 1010–1018.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., Zeng, D., Rush, A. J., and Kosorok, M. R. (2012), “Estimating Individualized Treatment Rules Using Outcome Weighted Learning,” Journal of the American Statistical Association, 107, 1106–1118.
   PubMed Web of Science ®Google Scholar